Brimonidine Tartrate
Brand names: Alphagan P, Brimonidine Tartrate
At a glance
- Medicare prescriptions, 2024
- 2,387,355
- Medicare drug cost
- $153.2M
- Average cost per prescription
- $64.19
- Clinicians who prescribed it
- 30,556
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
From the FDA-approved prescribing information (label dated September 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Ophthalmology 71.8%
- Optometrists 18.1%
- Internal Medicine 2.9%
- Retina Specialist 2.4%
- Family Medicine 1.8%
- Nurse Practitioners 1.1%
- Geriatric Medicine 0.6%
- General Practice 0.4%
- Physician Assistants 0.3%
- Hospitalist 0.2%
- Cardiology 0.0%
- Infectious Disease 0.0%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 9% from 2019 to 2024.
Biggest change by state since 2019
- Utah +46%
- Oklahoma +34%
- Virginia +28%
- Kansas +26%
- Delaware +26%
- Iowa (smallest change) −11%
- Vermont (smallest change) −7%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $541 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- AbbVie Inc. $541
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Jun 2020 · Somerset Therapeutics LLC · Class III
Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.